Recent actions from the Trump administration could signal limits to curtail Medicaid waivers related to social determinants of health and to limit waiver financing tools and flexibility. Two major changes demonstrate this shift: (1) rescinding Biden-era guidance on covering health-related social needs (HRSN) services, and (2) phasing out federal funding for “Designated State Health Programs”…
Here are five guidelines to help employers balance health outcomes and financial responsibility to ensure that GLP-1 coverage is effective, affordable, and aligned with improved health and workforce well-being for employees and their families. The post How Employers Can Build an Effective GLP-1 Strategy appeared first on MedCity News.
During HLTH 2024, Blue Shield of California and Salesforce announced a partnership that will streamline the prior authorization process. The post Blue Shield of California, Salesforce Partner to Modernize Prior Authorization appeared first on MedCity News.
This timeline provides a detailed overview of actions, including counter-actions, related to the administration’s efforts to freeze all U.S. foreign aid and dissolve the U.S. Agency for International Development (USAID).
Facing mounting losses, Walgreens announces the closure of 1,200 locations in the next three years
[Sponsored] In this episode, a pharmacy benefit management executive and a pharmacy startup talk about why benefit verification, prior authorizations, and patient affordability still break the workflow and how smart integrations, real-time eligibility, and intuitive design can reduce friction for all involved. The post MedCity Pivot Podcast: Price Transparency is the New North in the…
Jefferson’s Anna Flattau, M.D., M.S., says the NCQA program focuses not only on the content of the metrics but also on data reporting challenges
Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection. The post A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly appeared first on MedCity News.
Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad collaboration between Daiichi Sankyo and AstraZeneca. The post AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer appeared first on…
The European Union’s highest court sided with Illumina, agreeing that the European Commission had no authority to review the acquisition of liquid biopsy company Grail. The ruling comes after Illumina stopped challenging antitrust litigation, opting to instead spin out Grail as a standalone company. The post Illumina’s European Court Victory Can’t Salvage Grail Acquisition, But…